Related Experiment Videos
Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C
E Baudin1, P Marcellin, M Pouteau
1Service de Médecine Nucléaire, Hôpital Beaujon, Université Paris 7, Clichy, France.
Clinical Endocrinology
|December 1, 1993
Summary
Interferon therapy can cause thyroid dysfunction in 12% of patients, often linked to new thyroid autoantibodies. Fortunately, these interferon-induced thyroid disorders are reversible after treatment cessation.
Area of Science:
- Hepatology
- Endocrinology
- Immunology
Background:
- Thyroid dysfunction is a known complication of interferon therapy.
- Understanding risk factors and reversibility is crucial for patient management.
Purpose of the Study:
- To assess risk factors for interferon-induced thyroid disorders.
- To evaluate the reversibility of these thyroid conditions.
- To analyze thyroid function in patients undergoing interferon therapy for chronic hepatitis C.
Main Methods:
- Prospective study of 68 patients with chronic hepatitis C receiving interferon alpha 2b.
- Thyroid-stimulating hormone (TSH) and thyroid autoantibodies were monitored before, during, and after therapy.
- Hormonal studies and follow-up for at least one year were conducted for patients who developed thyroid dysfunction.
Main Results:
- 12% of patients (8/68) developed thyroid dysfunction (hypothyroidism or hyperthyroidism).
- The secondary appearance of thyroid autoantibodies during therapy was a significant risk factor.
- No pretreatment risk factors were identified.
Conclusions:
- Interferon therapy is associated with a 12% incidence of thyroid dysfunction.
- Elevated thyroid autoantibodies emerging during therapy indicate increased risk.
- Thyroid disorders induced by interferon are reversible, with normal function restored within 1.5 years post-treatment.